Association of PD-L1 Expression with Prognosis Among Patients with Ten Uncommon Advanced Cancers
Torben Steiniche(Aarhus University), Kai‐Li Liaw(United States Military Academy), Fan Jin(Second Affiliated Hospital of Xi'an Jiaotong University), Morten Ladekarl(Aalborg University Hospital), Matthew J. Marton(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Busch-Sørensen(Center for Clinical & Basic Research), Wei Zhou(Broad Institute), Simon Andreasen(Zealand University Hospital), Scott K. Pruitt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jeanette Bæhr Georgsen(Aarhus University Hospital)
Cited by 15
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
|Nature Communications|2021|386
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
|Proceedings of the National Academy of Sciences|2011|256